- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
BACKGROUND: Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD. METHODOLOGY/PRINCIPAL FINDINGS: The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR. We also measured CD4(+)FoxP3(+) regulatory T cells proportion by FACS analysis, microbiota composition by pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the numbers of CD4(+)FoxP3(+) regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory cytokines TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer's patches and large intestine, and changes the gut microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-α expression in RAW 264.7 cell line by down-regulating the NF-κB signaling pathway. CONCLUSION/SIGNIFICANCE: Our study provided evidence that even non-living probiotic bacteria can prevent the development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation of gut microenvironment.
- MeSH
- aktivace makrofágů účinky léků MeSH
- akutní nemoc MeSH
- aplikace orální MeSH
- down regulace účinky léků MeSH
- fosfoproteiny metabolismus MeSH
- imunita účinky léků MeSH
- kolitida mikrobiologie patologie patofyziologie prevence a kontrola MeSH
- Lactobacillus casei metabolismus MeSH
- lidé MeSH
- lipopolysacharidy farmakologie MeSH
- membránové proteiny metabolismus MeSH
- metagenom účinky léků MeSH
- myši inbrední BALB C MeSH
- myši SCID MeSH
- myši MeSH
- NF-kappa B metabolismus MeSH
- permeabilita účinky léků MeSH
- počet lymfocytů MeSH
- probiotika aplikace a dávkování farmakologie MeSH
- regulační T-lymfocyty cytologie účinky léků MeSH
- střevní sliznice účinky léků imunologie mikrobiologie MeSH
- TNF-alfa biosyntéza MeSH
- trávicí systém účinky léků mikrobiologie patofyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Commensal bacteria have been shown to modulate the host mucosal immune system. Here, we report that oral treatment of BALB/c mice with components from the commensal, Parabacteroides distasonis, significantly reduces the severity of intestinal inflammation in murine models of acute and chronic colitis induced by dextran sulphate sodium (DSS). The membranous fraction of P. distasonis (mPd) prevented DSS-induced increases in several proinflammatory cytokines, increased mPd-specific serum antibodies and stabilized the intestinal microbial ecology. The anti-colitic effect of oral mPd was not observed in severe combined immunodeficient mice and probably involved induction of specific antibody responses and stabilization of the intestinal microbiota. Our results suggest that specific bacterial components derived from the commensal bacterium, P. distasonis, may be useful in the development of new therapeutic strategies for chronic inflammatory disorders such as inflammatory bowel disease.
- MeSH
- akutní nemoc MeSH
- antigeny bakteriální aplikace a dávkování imunologie MeSH
- aplikace orální MeSH
- Bacteroides imunologie MeSH
- chronická nemoc MeSH
- cytokiny krev imunologie MeSH
- kolitida terapie MeSH
- metagenom imunologie MeSH
- myši inbrední BALB C MeSH
- myši SCID MeSH
- myši MeSH
- protilátky bakteriální krev imunologie MeSH
- střevní sliznice imunologie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
